Scientists discover potential to prevent cancer in children with neuroblastoma

Proudly supported by

  Last updated April 1, 2019 at 12:23 pm

Topics:  

New drug combination in clinical trials has the potential to prevent cancer in children.


childhood cancer neuroblastoma


A team including UNSW Sydney researchers has discovered the link between a cancer-causing gene and a group of molecules that helps cells grow, raising hopes that scientists will be able to develop new ways to treat and prevent neuroblastoma in children.


The MYCN oncogene has long been known to be a key cause of a number of deadly solid tumour cancers, including neuroblastoma, which claims more lives of children under the age of 5 than any other cancer. Neuroblastoma is the most common solid tumour found in young children. In up to 25% of cases, the tumours contain an increased number of copies of MYCN, and children with these ‘high-risk’ neuroblastomas have a particularly poor prognosis.


To date, no drugs have been able to directly target MYCN, so scientists have looked at other ways to halt the progress of neuroblastoma.


One group of target molecules, known as polyamines, are known to be critical for cell growth and survival and are present in high concentrations in cancer cells. However, clinical trials of agents that target the polyamine pathway have proven disappointing.


Unknown link between polyamines and MYCN


In new research published this week in the international journal Science Translational Medicine, a team jointly led by Professor Michelle Haber and Professor Murray Norris from the Children’s Cancer Institute, has uncovered a previously unknown and crucial link between polyamines and MYCN, revealing that the polyamine pathway is entirely regulated by the MYCN oncogene.


Discovering this link – by which MYCN controls polyamine levels in cancer cells, driving the growth and proliferation of the neuroblastoma cells – means that scientists for the first time have a potential therapeutic “way in” to disrupting cancer cell growth.


UNSW Conjoint Professor Michelle Haber AM


Previously, the Children’s Cancer Institute research team has shown that a drug called DFMO targets a gene involved in the synthesis of polyamines. There is a clinical trial underway at the Kids Cancer Centre, Sydney Children’s Hospital, and in 14 leading US children’s cancer centres, to study the use of DFMO when given with existing anti-cancer drugs, to treat children with relapsed neuroblastoma.


In the current study, researchers have identified the gene responsible for the uptake of polyamines by neuroblastoma cells and have shown that this gene can be inhibited using a drug called AMXT-1501. By combining these two drugs, DFMO and AMXT-1501, with conventional chemotherapy, the research team was able to significantly increase survival in mice with established neuroblastoma tumours, as well as prevent tumour formation in mice who were tumour-free but genetically prone to developing the disease.


Already into clinical trials


The newly discovered combination therapy is now being tested in the US in adult patients with a broad range of cancers, in Phase 1 clinical trials run by pharmaceutical company Aminex Therapeutics. The trial is listed on the NIH clinical trial registry at www.clinicaltrials.gov (Identifier NCT03536728).


“This exciting new treatment approach warrants clinical investigation in children with MYCN-driven high-risk neuroblastoma, and potentially other cancers as well,” said Professor Haber. “While other treatment approaches in clinical evaluation are designed to inhibit polyamine synthesis, they do not impact polyamine uptake from the microenvironment. Our study suggests that both polyamine synthesis and polyamine uptake need to be inhibited for therapy to be effective.”


Mark Burns PhD, President and Chief Scientific Officer at Aminex and an author on the paper, described the study’s results as “impressive” and said they further bolster the company’s excitement about the potential for polyamine depletion therapy as a new treatment approach.


“These findings demonstrate the benefit of combining inhibition of polyamine synthesis with blockade of polyamine transport and suggest that combining AMXT 1501 and DFMO with standard chemotherapy may be a potent treatment strategy for high-risk neuroblastoma patients,” he said.


Working with Aminex Therapeutics to lead the introduction of this new combination treatment for neuroblastoma into clinical trials is Associate Professor David Ziegler, paediatric oncologist at the Sydney Children’s Hospital and a research Group Leader at the Children’s Cancer Institute.


“These results are very exciting and offer a new and potent way to target childhood cancers,” said Associate Professor Ziegler. “We have already shown in our current clinical trial that targeting polyamines with one drug (DFMO) can be safely achieved in combination with chemotherapy. By combining two drugs targeting the same pathway we have the potential to further improve the anti-cancer effect for these children. We are now working with Aminex to develop a children’s formulation of AMXT1501 and once the initial adult trial is complete, we plan to open a clinical trial for children with the most aggressive cancers.”


Related


What is to blame for childhood cancer? We often misunderstand the reality


Childhood and adult cancers are different – and that’s good news for children


Why don’t elephants get cancer as often as others?




About the Author

UNSW Newsroom
The latest and best news from the University of New South Wales.

Published By

Featured Videos

Placeholder
Big Questions: Cancer
Placeholder
A future of nanobots in 180 seconds
Placeholder
Multi-user VR opens new worlds for medical research
Placeholder
Precision atom qubits achieve major quantum computing milestone
Placeholder
World's first complete design of a silicon quantum computer chip
Placeholder
Micro-factories - turning the world's waste burden into economic opportunities
Placeholder
Flip-flop qubits: a whole new quantum computing architecture
Placeholder
Ancient Babylonian tablet - world's first trig table
Placeholder
Life on Earth - and Mars?
Placeholder
“Desirable defects: Nano-scale structures of piezoelectrics” – Patrick Tung
Placeholder
Keeping Your Phone Safe from Hackers
Placeholder
Thru Fuze - a revolution in chronic back pain treatment (2015)
Placeholder
Breakthrough for stem cell therapies (2016)
Placeholder
The fortune contained in your mobile phone
Placeholder
Underwater With Emma Johnston
Placeholder
Flip-flop qubits: a whole new quantum computing architecture
Placeholder
The “Dressed Qubit” - breakthrough in quantum state stability (2016)
Placeholder
Pinpointing qubits in a silicon quantum computer (2016)
Placeholder
How to build a quantum computer in silicon (2015)
Placeholder
Quantum computer coding in silicon now possible (2015)
Placeholder
Crucial hurdle overcome for quantum computing (2015)
Placeholder
New world record for silicon quantum computing (2014)
Placeholder
Quantum data at the atom's heart (2013)
Placeholder
Towards a quantum internet (2013)
Placeholder
Single-atom transistor (2012)
Placeholder
Down to the Wire (2012)
Placeholder
Landmark in quantum computing (2012)
Placeholder
1. How Quantum Computers Will Change Our World
Placeholder
Quantum Computing Concepts – What will a quantum computer do?
Placeholder
Quantum Computing Concepts – Quantum Hardware
Placeholder
Quantum Computing Concepts – Quantum Algorithms
Placeholder
Quantum Computing Concepts – Quantum Logic
Placeholder
Quantum Computing Concepts – Entanglement
Placeholder
Quantum Computing Concepts - Quantum Measurement
Placeholder
Quantum Computing Concepts – Spin
Placeholder
Quantum Computing Concepts - Quantum Bits
Placeholder
Quantum Computing Concepts - Binary Logic
Placeholder
Rose Amal - Sustainable fuels from the Sun
Placeholder
Veena Sahajwalla - The E-Waste Alchemist
Placeholder
Katharina Gaus - Extreme Close-up on Immunity
Placeholder
In her element - Professor Emma Johnston
Placeholder
Martina Stenzel - Targeting Tumours with Tiny Assassins
Placeholder
How Did We Get Here? - Why are we all athletes?
Placeholder
How Did We Get Here? - Megafauna murder mystery
Placeholder
How Did We Get Here? - Why are we so hairy?
Placeholder
How Did We Get Here? - Why grannies matter
Placeholder
How Did We Get Here? - Why do only humans experience puberty?
Placeholder
How Did We Get Here? - Evolution of the backside
Placeholder
How Did We Get Here? - Why we use symbols
Placeholder
How Did We Get Here? - Evolutionary MasterChefs
Placeholder
How Did We Get Here? - The Paleo Diet fad
Placeholder
How Did We Get Here? - Are races real?
Placeholder
How Did We Get Here? - Are We Still Evolving?
Placeholder
How Did We Get Here? - Dangly Bits
Placeholder
Catastrophic Science: Climate Migrants
Placeholder
Catastrophic Science: De-Extinction
Placeholder
Catastrophic Science: Nuclear Disasters
Placeholder
Catastrophic Science: Storm Surges
Placeholder
Catastrophic Science: How the Japan tsunami changed science
Placeholder
Catastrophic Science: How the World Trade Centre collapsed
Placeholder
Catastrophic Science: Bushfires